+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study

Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study

European Journal of Clinical Microbiology and Infectious Diseases 33(1): 55-59

This study was performed to evaluate the clinical features of community-onset levofloxacin-nonsusceptible pneumococcal pneumonia and to identify risk factors for levofloxacin resistance. Using the database of a surveillance study of community-acquired pneumococcal infections in Asian countries, we conducted a nested case-control study to identify risk factors for levofloxacin-nonsusceptible S. pneumoniae in community-acquired pneumonia in adults. Of 981 patients with pneumococcal pneumonia, 46 (4.7 %) had levofloxacin-nonsusceptible S. pneumoniae, of whom 39 evaluable cases were included in the analysis. All cases were from Korea, Taiwan, and Hong Kong. Among patients with levofloxacin-susceptible S. pneumoniae, 490 controls were selected based on patient country. Of the 39 cases of levofloxacin-nonsusceptible pneumococcal pneumonia, 23 (59.0 %) were classified as healthcare-associated, while 164 (33.5 %) of the 490 controls of levofloxacin-susceptible S. pneumoniae (P = 0.001) were classified as healthcare-associated. Multivariate analysis showed that previous treatment with fluoroquinolones, cerebrovascular disease, and healthcare-associated infection were significantly associated with levofloxacin-nonsusceptible pneumococcal pneumonia (all P < 0.05). Levofloxacin-nonsusceptible pneumococci pose an important new public health threat in our region, and more information on the emergence and spread of these resistant strains will be necessary to prevent spread throughout the population.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055581857

Download citation: RISBibTeXText

PMID: 24062235

DOI: 10.1007/s10096-013-1928-3

Related references

Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae. Microbial Drug Resistance 24(9): 1412-1416, 2018

The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 32(19): 2198-2203, 2014

Outcome of penicillin-nonsusceptible Streptococcus Pneumoniae meningitis A nested case-control study. Pediatric Research 47(4 Part 2): 266A, 2000

Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatric Infectious Disease Journal 21(10): 903-910, 2002

Risk factors for community-acquired pneumonia in children under five years of age in the post-pneumococcal conjugate vaccine era in Brazil: a case control study. Bmc Pediatrics 16(1): 157-157, 2016

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clinical Infectious Diseases 32(5): 701-707, 2001

Bacteremic treatment failure with azithromycin in community-acquired pneumococcal pneumonia A report of 3 patients infected with erythromycin-resistant and penicillin- and cephaloxporin-nonsusceptible strains, treated successfully with levofloxacin. Abstracts Of The Interscience Conference On Antimicrobial Agents & Chemotherapy. 38: 578-579, 1998

Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. British Journal of Clinical Pharmacology 83(9): 2034-2044, 2017

Efficacy of levofloxacin in the treatment of community-acquired pneumonia due to penicillin- and macrolide-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 44(Suppl. A): 130, 1999

Macrolide-resistant Streptococcus pneumoniae in community-acquired pneumonia: Clinical and microbiological outcomes for patients treated with levofloxacin. Clinical Infectious Diseases 38(Suppl. 1): S24-S33, 15 January, 2004

Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 372(9636): 398-405, 2008

Evaluation of a nested-PCR assay for Streptococcus pneumoniae detection in pediatric patients with community-acquired pneumonia. Revista Argentina de Microbiologia 37(4): 184-188, 2006

Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. International Journal of Antimicrobial Agents 26(2): 120-125, 2005

Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema. Enfermedades Infecciosas Y Microbiologia Clinica 23(5): 270-273, 2005

Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatric Infectious Disease Journal 29(12): 1099, 2010